Table 1 Indications and the dose regimen for usage of DOACs
From: An update on applications and limitations of direct oral anticoagulants
DOAC | VTE treatment and prophylaxis | Non-valvular atrial fibrillation | Prophylaxis of VTE post hip surgeries | Renal dosing in ESRD |
|---|---|---|---|---|
Apixaban (Eliquis) | 10 mg twice daily for 1 week, then 5 mg twice daily | 5 mg twice daily | 2.5 mg twice daily | 5 mg twice daily CrCl > 50 mL/min; or 2.5 mg twice daily for those with any two of the following: age ≥ 80 years, weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL. Dose adjustment is required in patients with CrCl < 15 ml/min |
Rivaroxaban (Xarelto) | 15 mg twice daily with food for 3 weeks; then 20 mg once daily with food | 20 mg once daily with food | 10 mg once daily, with or without food | For AF, 20 mg once daily for CrCl > 50 mL/min and 15 mg once daily for CrCl ≤ 50 mL/min. Contraindicated in patients with CrCl < 15 ml/min |
Edoxaban (Lixiana) | Parenteral anticoagulation for 5 to 10 days; then edoxaban 60 mg once daily | 60 mg once daily |  | Contraindicated in patients with CrCl > 95 and < 15 mL/min; for CrCl 15–50 mL/min dose reduction to 30 mg once daily |
Dabigatran (Pradaxa) | Parenteral anticoagulation for 5 to 10 days; then dabigatran 150 mg twice daily | 150 mg twice daily | 110 mg for the first day, then 220 mg once daily | Dose reduction to 75 mg twice daily in CrCl 15–30 mL/min, contraindicated in CrCl < 15 mL/min |